You are here: Industry Insights > Diurnal

News List

First adrenal insufficiency patient dosed in Phase 2 study pharmatimes
February 10, 2022
Diurnal’s pioneering phase 2 study evaluates modified-release hydrocortisone for adrenal insufficiency.
MHRA authorises Diurnal’s CAH therapy Efmody pharmatimes
July 02, 2021
Speciality pharma company Diurnal announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Efmody a marketing authorisation in Great Britain.
EC authorises Diurnal’s Efmody for CAH pharmatimes
June 02, 2021
The European Commission (EC) has approved UK-headquartered pharma company Diurnal’s Efmody for the treatment of congenital adrenal hyperplasia (CAH).
Diurnal seeks marketing authorisation for Chronocort in the UK pharmatimes
January 14, 2021
UK speciality pharma Diurnal has submitted a marketing authorisation application for Chronocort (modified-release hydrocortisone) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for patients with the rare condition congenital ...
EffRx Pharmaceuticals signs exclusive license agreement with Diurnal for registration and commercialisation of Alkindi pharmaceutical-business-review
October 26, 2020
EffRx Pharmaceuticals SA announced it has recently entered into an exclusive license agreement with Diurnal Group plc for the registration and commercialization of Alkindi for pediatric adrenocortical insufficiency (AI) in Switzerland.
Diurnal shares plummet on trial failure pharmatimes
October 11, 2018
Shares in UK speciality pharma Diurnal plummeted more than 50 percent on news that a late-stage study of an experimental treatment...